Abstract 187P
Background
Few reports address the impact of surgery on the prognosis of rare and heterogeneous gastric neuroendocrine carcinoma (G-NEC). This study analyzed the influence of surgical treatments on prognosis to provide a personalized surgical treatment strategy for G-NEC patients.
Methods
The clinicopathological data of 964 G-NEC patients from 24 Chinese hospitals were analyzed. Cox regression analyses were used to analyze the prognostic factors affecting survival and recurrence, respectively.
Results
Cox analysis revealed that in stage I-II but not stage III gastric neuroendocrine carcinoma/mixed adenoneuroendocrine carcinoma (NEC/MANEC) patients, D2 (extended) lymph node dissection (ELND) was an independent protective factor for OS and DFS (p<0.05; p<0.05). In stage I-II, 3-year OS and DFS increased with more of LNs dissected (p<0.05), while in stage III patients undergoing ELND, the 3-year OS and DFS was similar to patients undergoing D1+ (limited) lymph node dissection (LLND) (p>0.05). Furthermore, among patients with stage III disease, the incidence of complications after ELND was significantly greater than that after LLND (28.4% vs. 12.1%, p < 0.001), especially severe complications (Clavien-Dindo grade III-V). For patients with stage I-II disease, ELLN not only brings lower overall recurrence rate (ELND vs. LLND = 16.9% vs 27.6%, p = 0.018) but also reduced the risk of regional LN and distant LN recurrence (all p < 0.05).
Conclusions
ELND may lead to enhanced long-term survival for stage I and II but not stage III NEC/MANEC patients. Our results in multicenter patients do not support the routine use of ELND in stage III NEC/MANEC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
244P - Optimization of early diagnostics of cervical intraepitelial neoplasies and cervical cancer
Presenter: Zakhirova Nargiza
Session: e-Poster Display Session
245P - Clinicopathological features including response to platinum-based chemotherapy in endometrial carcinomas involving SWI/SNF complex inactivation.
Presenter: Izumi Tanimoto
Session: e-Poster Display Session
246P - Impact of genetically predicted elevated concentrations of C-reactive protein on ovarian cancer risk: A Mendelian randomization study
Presenter: Haoxin Peng
Session: e-Poster Display Session
247P - The role of p53 gene suppressor and bcl-2 oncoprotein in non-epithelial ovarian tumor prognosis determination among child and adolescent patients
Presenter: Anvar Shukullaev
Session: e-Poster Display Session
248P - The effect of progesterone on ALA-based PDT efficacy in uterine sarcoma cells
Presenter: Ellie Chu
Session: e-Poster Display Session
249P - A Retrospective Study on the Treatment Response of Locally Advanced Cervical Cancer Patients to Combination Chemoradiotherapy
Presenter: Siti Nabihah Sahralidin
Session: e-Poster Display Session
250P - Health-related Quality of Life in Women with Cervical Cancer
Presenter: Almagul Zhabagina
Session: e-Poster Display Session
251P - Tendency of morbidity and mortality in cervical cancer in the last 10 years in the Republic of Uzbekistan
Presenter: Mirzagaleb Tillyashaykhov
Session: e-Poster Display Session
252P - Secondary data analysis of newly diagnosed advanced ovarian cancer in South Korea
Presenter: Soo Young Jeong
Session: e-Poster Display Session
253P - Non-Epithelial Tumours of Ovary, An Experience from Qatar
Presenter: Ammar Madani
Session: e-Poster Display Session